NeuroCytotron in the Treatment of Autism Spectrum Disorder

NCT06477263 | Recruiting

• 1 other identifier: NCX-ASD-01
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Preliminary Efficacy and Feasibility of Using NeuroCytotron in the Treatment of Autism Spectrum Disorder

Conditions

Autism Spectrum Disorder

Outcome Measures

Primary Outcomes (11)

• Changes in Autism Diagnostic Observation Schedule-Second Edition scale scores

  * Variables related to social communication, such as quality of social interaction, emotional reciprocity, and verbal and nonverbal communication. * Variables related to repetitive and stereotyped behavior, such as repetitive motor movements and restricted interests or behaviors. * Autism Diagnostic Observation Schedule-Second Edition total score as a global measure of Autism Spectrum Disorder symptoms. The Autism Diagnostic Observation Schedule-Second Edition scores range from 0 to 24, where higher scores indicate a greater severity of Autism Spectrum Disorder symptoms

  Through study completion, an average of 1 year

• Changes in Adaptive Behavioral Assessment System scores

  * Variables related to adaptive skills in areas such as communication, daily living, personal autonomy and social skills. * Total adaptive skills scores to assess overall functioning in different adaptive domains. The Autism Diagnostic Observation Schedule-Second Edition scores range from 0 to 24, where higher scores indicate a greater severity of Autism Spectrum Disorder symptoms The Adaptive Behavioral Assessment System scores range from 40 to 160, where higher scores indicate better adaptive functioning

  Through study completion, an average of 1 year

• Changes in Childhood Autism Rating Scale scores

  * Variables related to the severity of ASD symptoms, including aspects such as social relationship, communication, stereotyped behavior and eye contact. * Childhood Autism Rating Scale total score as a global measure of Autism Spectrum Disorder symptom severity. The Childhood Autism Rating Scale scores range from 15 to 60, where higher scores indicate a greater severity of autism symptoms

  Through study completion, an average of 1 year

• Changes in Gilliam Autism Measurement Scale score

  * Variables related to the severity of ASD symptoms, including areas such as social interaction, communication, stereotyped behaviors, and restricted interests. * Specific subscales of the Gilliam Autism Measurement Scale that assess different dimensions of Autism Spectrum Disorder symptoms. The Gilliam Autism Measurement Scale scores range from 0 to 174, where higher scores indicate a greater severity of autism symptoms

  Through study completion, an average of 1 year

• Withdrawal Rate

  • To assess the study withdrawal rate to NeuroCytotron treatment to determine the feasibility and acceptability of treatment by subjects and caregivers.

  Through study completion, an average of 1 year

• Adherence to Treatment

  • To assess the adherence to NeuroCytotron treatment to determine the feasibility and acceptability of treatment by subjects and caregivers.

  Through study completion, an average of 1 year

• Treatment Security

  • Record any treatment-related adverse events to assess the safety of NeuroCytotron in this subject population.

  Through study completion, an average of 1 year

• Change in the number of seizures or epileptic seizures during the study period

  • Obtain information on the number of seizures (if any) before and after treatment.

  Through study completion, an average of 1 year

• Neurophysiological changes: in functional activity and brain anatomy using Magnetic Resonance Imaging

  * Representative, visual, motor, basal ganglia and other modules * Total brain volume * Frontal and temporal lobe volume * Cortical thickness in the frontal lobe * Surface area and cortical gyrification and cerebrospinal fluid volume * Cerebellum volume * Volume of the corpus callosum * White matter, hippocampus, amygdala, thalamus, and basal ganglia The above describes one assessment where several anatomical regions are imaged via Magnetic Resonance Imaging - sequence T1

  Through study completion, an average of 1 year

• Neurophysiological changes: in functional activity and brain anatomy using Diffusion Tensor Imaging

  • Diffusion Tensor Imaging data, as an increase in the values of the anisotropy fractions (AF)

  Through study completion, an average of 1 year

• Neurophysiological changes: in functional activity and brain anatomy using Electroencephalogram

  • Brain activities during resting states.

  Through study completion, an average of 1 year

Secondary Outcomes (5)

• Changes in comorbid symptoms

  Through study completion, an average of 1 year

• Changes in sensory processing: hypersensitivity by percentile ranks

  Through study completion, an average of 1 year

• Changes in sensory processing: hypersensitivity by classification scores

  Through study completion, an average of 1 year

• Changes in sensory processing: hyposensitivity by percentile ranks

  Through study completion, an average of 1 year

• Changes in sensory processing: hyposensitivity by classification scores

  Through study completion, an average of 1 year

Study Arms (1)

Arm One

EXPERIMENTAL

All participants

Device: Neurocytotron

Interventions

Neurocytotron DEVICE

Neuronal regeneration treatment

Arm One

Eligibility Criteria

• Age: 3 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Male or female subjects with a confirmed diagnosis of ASD according to DSM-5 criteria.
• Subjects ≥ 3 and ≤ 50 years.
• Subjects with ASD severity grade 1 to 3 according to DSM-5 criteria.
• To have the informed consent of the parents or legal representatives for the subject's participation in the study.
• Subjects must be physically able and willing to undergo the treatment sessions.
• Subjects must be medically and psychologically stable to participate in the study.

You may not qualify if:

• Presence of medical conditions that could contraindicate the use of NeuroCytotron DM, such as severe neurological disorders and difficult-to-control epilepsy.
• uncontrolled epilepsy is defined as: more than 1 generalized seizure in any month within the 3 months prior to the day 1 visit, or
• history of any of the following within 9 months prior to the day 1 visit: prolonged seizures or repetitive seizure activity requiring administration of a rescue benzodiazepine (oral, rectal, etc.) more than once a month, seizures lasting more than 10 minutes, status epilepticus or epilepsy with autonomic involvement.
• Concurrent participation in other therapies or interventions for autism during the study period.
• Logistical or situational limitations that prevent regular attendance at treatment sessions.
• History of significant adverse reactions to similar treatments or involving the use of anesthesia.
• Presence of serious behavioral problems or aggression that may affect the safety of the subject or staff during treatment sessions.
• Current or recent (previous 14 days) history of clinically significant bacterial, fungal, viral or mycobacterial infection.
• Subjects with magnetic implants, pacemakers, claustrophobia or any other condition that prevents them from entering or remaining in the DM NeuroCytotron.

Sponsors & Collaborators

• Neurocytonix, Inc.: lead

Study Sites (1)

NeuroCytonix México

San Pedro Garza García, Nuevo León, 66224, Mexico

RECRUITING

MeSH Terms

Conditions

Autism Spectrum Disorder

Condition Hierarchy (Ancestors)

Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Mental Disorders

Study Officials

• J R Trujillo

  jrtrujillo@neurocytonix.com

  STUDY CHAIR

• Lorenzo R Morales Mancias

  NeuroCytonix Mexico

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Karen Camarillo Cardenas

CONTACT

+528135414706; kcamarillo@neurocytonix.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 5, 2024
• First Posted: June 27, 2024
• Study Start: July 15, 2024
• Primary Completion: March 6, 2025
• Study Completion: September 30, 2025
• Last Updated: February 6, 2025

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

ME (1)